NASDAQ:VSTM Verastem Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.20 +0.05 (+4.35%) (As of 06/29/2022 04:00 PM ET) Add Compare Share Today's Range$1.12▼$1.2250-Day Range$1.02▼$1.5852-Week Range$1.00▼$4.17Volume1.22 million shsAverage Volume2.21 million shsMarket Capitalization$223.63 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Stock Forecast (MarketRank)Overall MarketRank™2.23 out of 5 starsMedical Sector351st out of 1,432 stocksPharmaceutical Preparations Industry150th out of 685 stocksAnalyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Verastem has a forecasted upside of 358.3% from its current price of $1.20.Amount of Analyst CoverageVerastem has only been the subject of 2 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesVerastem has received 582 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVerastem has received 275 “underperform” votes. (Add your “underperform” vote.)Community SentimentVerastem has received 67.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote “Outperform” if you believe VSTM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,710.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Verastem is held by insiders.Percentage Held by Institutions73.25% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($0.39) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verastem (NASDAQ:VSTM)Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More VSTM Stock News HeadlinesJune 29, 2022 | seekingalpha.comVerastem Stock: Looking Increasingly Attractive (NASDAQ:VSTM) - Seeking AlphaJune 27, 2022 | finance.yahoo.comWhat You Need To Know About Verastem, Inc.'s (NASDAQ:VSTM) Investor CompositionJune 20, 2022 | americanbankingnews.comBrokerages Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $5.67June 9, 2022 | americanbankingnews.comVerastem, Inc. Expected to Earn FY2023 Earnings of ($0.26) Per Share (NASDAQ:VSTM)June 8, 2022 | streetinsider.comForm 8-K Verastem, Inc. For: Jun 06 - StreetInsider.comJune 7, 2022 | benzinga.comVerastem Oncology's Return On Capital Employed Insights - Benzinga - BenzingaJune 7, 2022 | seekingalpha.comVerastem VS-6766 shows promise in phase 2 ovarian cancer study - Seeking AlphaJune 7, 2022 | businesswire.comVerastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer - Business WireJune 6, 2022 | streetinsider.comVerastem Oncology (VSTM) Issues Update on RAMP 201 Study of VS-6766 ± Defactinib - StreetInsider.comJune 6, 2022 | finance.yahoo.comVerastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian CancerMay 21, 2022 | nasdaq.com7 Cheap Biotech Stocks to Buy Now - NasdaqMay 20, 2022 | seekingalpha.comVerastem gets $3.8M award for VS-6766/defactinib combo trial to treat pancreatic cancer - Seeking AlphaMay 18, 2022 | businesswire.comVerastem Oncology Awarded Pancreatic Cancer Action Network's First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer - Business WireSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees48Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/29/2022Next Earnings (Estimated)8/01/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$6.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+358.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71.20 million Net Margins-2,007.44% Pretax Margin-2,007.44% Return on Equity-84.99% Return on Assets-63.51% Debt Debt-to-Equity Ratio0.34 Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual Sales$2.05 million Price / Sales109.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book2.50Miscellaneous Outstanding Shares186,361,000Free Float180,397,000Market Cap$223.63 million OptionableOptionable Beta0.89 Verastem Frequently Asked Questions Should I buy or sell Verastem stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verastem stock. View analyst ratings for Verastem or view top-rated stocks. What is Verastem's stock price forecast for 2022? 5 analysts have issued 1 year price objectives for Verastem's stock. Their VSTM stock forecasts range from $5.00 to $6.00. On average, they expect Verastem's stock price to reach $5.50 in the next year. This suggests a possible upside of 358.3% from the stock's current price. View analysts' price targets for Verastem or view top-rated stocks among Wall Street analysts. How has Verastem's stock performed in 2022? Verastem's stock was trading at $2.05 at the beginning of the year. Since then, VSTM stock has decreased by 41.5% and is now trading at $1.20. View the best growth stocks for 2022 here. When is Verastem's next earnings date? Verastem is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022. View our earnings forecast for Verastem. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) announced its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $2.60 million for the quarter, compared to analyst estimates of $2.50 million. Verastem had a negative trailing twelve-month return on equity of 84.99% and a negative net margin of 2,007.44%. View Verastem's earnings history. Who are Verastem's key executives? Verastem's management team includes the following people: Mr. Brian M. Stuglik BPHARM, R.Ph., RPh, CEO & Director (Age 63, Pay $1.04M)Mr. Daniel W. Paterson, COO & Pres (Age 61, Pay $710.39k)Mr. Robert E. Gagnon, Chief Bus. & Financial Officer (Age 48, Pay $609.39k) (LinkedIn Profile)Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 68)Dr. Robert A. Weinberg Ph.D., Co-Founder & Chair of Scientific Advisory BoardDr. Piyush B. Gupta Ph.D., Co-FounderDr. Michelle Dipp M.D., Ph.D., Co-Founder (Age 46)Dr. Jonathan Pachter Ph.D., Chief Scientific Officer (Age 64)Ms. Erin S. Cox, Sr. Director of Investor Relations & Corp. CommunicationsMr. Sean C. Flynn, VP, Gen. Counsel & Sec. (Age 48) What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem CEO Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among Verastem's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Verastem's key competitors? Some companies that are related to Verastem include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of VSTM's competitors. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX). What is Verastem's stock symbol? Verastem trades on the NASDAQ under the ticker symbol "VSTM." Who are Verastem's major shareholders? Verastem's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.54%), Vanguard Group Inc. (4.72%), Eagle Asset Management Inc. (2.48%), State Street Corp (1.67%), Dimensional Fund Advisors LP (1.00%) and Renaissance Technologies LLC (0.90%). Company insiders that own Verastem stock include Brian M Stuglik, Dan Paterson, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich. View institutional ownership trends for Verastem. Which major investors are selling Verastem stock? VSTM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Panagora Asset Management Inc., Dimensional Fund Advisors LP, Bank of America Corp DE, UBS Group AG, Acadian Asset Management LLC, ClariVest Asset Management LLC, and Raymond James & Associates. Company insiders that have sold Verastem company stock in the last two years include Brian M Stuglik, Dan Paterson, and Robert E Gagnon. View insider buying and selling activity for Verastem or view top insider-selling stocks. Which major investors are buying Verastem stock? VSTM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eagle Asset Management Inc., Ergoteles LLC, Wetherby Asset Management Inc., Goldman Sachs Group Inc., Hsbc Holdings PLC, Samalin Investment Counsel LLC, and XTX Topco Ltd. View insider buying and selling activity for Verastem or or view top insider-buying stocks. How do I buy shares of Verastem? Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verastem's stock price today? One share of VSTM stock can currently be purchased for approximately $1.20. How much money does Verastem make? Verastem (NASDAQ:VSTM) has a market capitalization of $223.63 million and generates $2.05 million in revenue each year. The biopharmaceutical company earns $-71.20 million in net income (profit) each year or ($0.41) on an earnings per share basis. How many employees does Verastem have? Verastem employs 48 workers across the globe. How can I contact Verastem? Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for Verastem is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at [email protected]. This page (NASDAQ:VSTM) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here